EU Fines Lundbeck $125.6M In Pay-For-Delay Probe

Law360, New York (June 19, 2013, 12:31 PM EDT) -- The European Commission hit Danish H. Lundbeck A/S on Wednesday with $125.6 million in fines after finding that the drugmaker didn't lawfully protect its patents but instead violated antitrust rules by paying off generics competitors to keep cheaper versions of its antidepressant citalopram off the market.

Lundbeck allegedly cut so-called pay-for-delay deals in 2002 with several companies including Merck KGaA, Ranbaxy Laboratories Ltd. and Xellia Pharmaceuticals AS, providing lump sums to prevent generic versions of its blockbuster drug from being released, the commission said. A three-year...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.